Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer

Author: Hori Natsuko  

Publisher: Springer Publishing Company

ISSN: 1341-9625

Source: International Journal of Clinical Oncology, Vol.18, Iss.3, 2013-06, pp. : 435-438

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content